This content is from: Premium Hedge-Fund-Backed Acelyrin Makes a Strong IPO Debut In a brutal IPO environment, the biopharma company soared 30 percent in its first day of trading. By Gary Perkinson May 09, 2023
This content is from: Premium This Could Be the Next Biopharma IPO Several major hedge funds are poised to benefit if Acelyrin’s offering is successful. By Stephen Taub April 24, 2023
This content is from: Premium Institutional Investors More Than Doubled Their Hedge Fund Allocations Last Year Here’s a look at last year’s biggest allocators — and the top hedge fund recipients. By Stephen Taub March 21, 2023
This content is from: Premium Hedge Fund Favorites Outpace the Markets in the First Quarter Two companies heavily skewed the first-quarter results of the 15 stocks most widely held by hedge funds. By Stephen Taub April 04, 2023
This content is from: Premium Nvidia Surge Boosts Hedge Funds Almost 200 funds now have positions in the high-flying chipmaker, which is up 142 percent since October. By Stephen Taub March 24, 2023
This content is from: Premium The Complete Rich List: The 22nd Annual Ranking of the Highest-Earning Hedge Fund Managers It was a bad year for many of the usual suspects — but not for Ken Griffin. By Stephen Taub March 07, 2023
